Alzheimer’s Blood Test Gets FDA Clearance: What It Means

Key takeaways

• Roche and Eli Lilly’s Alzheimer’s blood test has received clearance from the US Food and Drug Administration.
• The test checks blood for a protein linked to Alzheimer’s brain changes.
• It may reduce the need for costly brain scans or spinal fluid tests.
• Doctors still need symptoms, medical history and other checks before making a diagnosis.

Roche and Eli Lilly’s Alzheimer’s blood test has won clearance from the US Food and Drug Administration. An Alzheimer’s blood test is a lab check that looks for signs of the disease in a blood sample. The new test could make early testing easier, but it cannot replace a doctor’s full review.

What does the Alzheimer’s blood test measure?

The test measures a protein called phosphorylated tau 217, or p-tau217. This protein tends to rise when Alzheimer’s causes harmful amyloid and tau changes in the brain.

Think of p-tau217 as a warning signal, not a final answer. A high level can point to Alzheimer’s-related changes, while a low level can make them less likely. Doctors must still consider other causes of memory loss.

Roche developed the Elecsys pTau217 plasma biomarker test with support from Eli Lilly. The test is designed for people aged 50 and older who show signs or symptoms of cognitive decline.

“The FDA clearance means this blood test can help doctors assess whether Alzheimer’s-related brain changes may be present,” Roche said in its announcement. It does not mean every person with a positive result has dementia.

Why the Alzheimer’s blood test matters

Doctors have traditionally used brain scans or spinal fluid tests to look for Alzheimer’s biology. Brain scans can cost thousands of dollars, while spinal fluid tests require a needle in the lower back.

A blood draw is simpler. It can also reach more people, especially those who live far from specialist clinics. That matters because Alzheimer’s affects millions of people, yet many patients wait months for a clear assessment.

Roche reported that the test showed 97% positive predictive value and 97% negative predictive value in its supporting study. Positive predictive value means how often a positive result matches the disease. Negative predictive value means how often a negative result correctly rules it out.

Reported study resultsPositive result match97%Negative result match97%

These figures sound strong, but they don’t promise perfect results for every patient. Test accuracy can change with age, symptoms, health history and the group being tested.

How will doctors use the Alzheimer’s blood test?

The test is meant to support a wider medical assessment. A doctor may first ask about memory, sleep, mood, medicines and daily tasks.

The clinician may then order the blood test. If the result points to Alzheimer’s, the doctor could request a brain scan or another test before discussing treatment.

This step matters because new Alzheimer’s drugs can carry serious risks. Treatments such as donanemab, sold by Lilly as Kisunla, target amyloid in the brain. They can cause brain swelling or small bleeds, so doctors need strong evidence before treatment.

The blood test may also help doctors decide who should receive further testing. As a result, it could reduce unnecessary scans while sending higher-risk patients to specialists sooner.

What the FDA clearance does not mean

FDA clearance is not the same as a cure or a guarantee of diagnosis. The FDA is the US agency that checks whether medical products meet safety and performance standards.

The test does not measure memory itself. It also cannot tell a family exactly when symptoms will worsen. Some people may have Alzheimer’s-related brain changes but no major problems in daily life.

Doctors must also rule out other causes. Depression, poor sleep, thyroid problems, vitamin shortages and some medicines can affect memory. A blood test alone cannot separate all these conditions.

Question	What the test can do	What it cannot do
What is measured?	p-tau217 in blood	Overall memory ability
Who is it for?	Adults 50+ with cognitive symptoms	Everyone as a general screening test
How is it used?	Supports a doctor’s assessment	Replaces every scan or exam
What may follow?	More tests or treatment discussion	A certain prediction of future decline

The FDA’s consumer guidance on Alzheimer’s diagnostic tests explains why test results need medical context. The National Institute on Aging also describes how doctors assess how Alzheimer’s disease is diagnosed.

When could patients get the Alzheimer’s blood test?

FDA clearance allows the test to move into clinical use in the United States. Availability will depend on laboratories, doctors, local rules and insurance coverage.

Patients may not see it at every clinic right away. Labs must set up the equipment, train staff and decide how to report results. Doctors must also learn where the test fits in their care plans.

The development adds to a wider shift toward simpler Alzheimer’s testing. It follows growing interest in blood markers that can show brain disease without a scan. But experts still need to watch how the test performs in everyday clinics.

For families, the clearest takeaway is simple: the test may speed up a difficult process, but a positive result starts a conversation. It does not finish one.

FAQs

What is an Alzheimer’s blood test?

It is a blood test that checks for p-tau217, a protein linked to Alzheimer’s-related brain changes.

Who can use the Alzheimer’s blood test?

The cleared test is intended for adults aged 50 and older who have signs or symptoms of cognitive decline.

Can the Alzheimer’s blood test diagnose dementia alone?

No. Doctors must combine the result with symptoms, medical history and other tests.